Jump­ing ahead of As­traZeneca, Ab­b­Vie and J&J get a green light to mar­ket Im­bru­vi­ca/Rit­ux­an com­bo for rare lym­phoma

Build­ing on some sol­id da­ta, Ab­b­Vie and J&J to­day land­ed an FDA OK to sell a chemo-free com­bi­na­tion of their BTK in­hibitor Im­bru­vi­ca with Roche’s Rit­ux­an for a rare and in­cur­able type of non-Hodgkin’s lym­phoma. 

The agency came through af­ter re­searchers post­ed an 82% sur­vival rate af­ter 30 months for pa­tients with Walden­ström’s macroglob­u­line­mia — on­ly 28% pa­tients get­ting on­ly Rit­ux­an sur­vived that long.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.